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Abstract:  Lewis (y) antigen is a difucosylated oligosaccharide present on the plasma 
membrane, and its overexpression is frequently found in human cancers and has been 
shown to be associated with poor prognosis. Our previous studies have shown that Lewis 
(y) antigen plays a positive role in the process of invasion and metastasis of ovarian cancer 
cells. However, the mechanisms by which Lewis (y) antigen enhances the invasion and 
tumor metastasis are still unknown. In this study, we established a stable cell line 
constitutively expressing Lewis (y) antigen (RMG-1-hFUT) by transfecting the cDNA 
encoding part of the human α1,2-fucosyltransferase (α1,2-FUT) gene into the ovarian 
cancer cell line RMG-1, and investigated whether Lewis (y) antigen regulates the 
expression of matrix metalloproteinase-2 (MMP-2) and MMP-9, and tissue inhibitors of 
metalloproteinases (TIMP-1) and TIMP-2. We found that RMG-1-hFUT cells exhibited 
higher invasive capacities than their control cells. In addition, expression of TIMP-1 and 
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TIMP-2 was down-regulated and expression of MMP-2 and MMP-9 was up-regulated. 
Anti-Lewis (y) antigen antibody treatment significantly reversed the expression of TIMP-1, 
TIMP-2, MMP-2 and MMP-9. Taken together, we provide the first evidence that   
down-regulation of TIMP-1 and TIMP-2 and up-regulation of MMP-2 and MMP-9 
represents one of the mechanisms by which Lewis (y) antigen promotes cell invasion. 
Keywords:  Lewis (y) antigen; matrix metalloproteinases; tissue inhibitors of 
metalloproteinases; invasion 
 
1. Introduction 
Lewis (y) antigen is a difucosylated oligosaccharide containing two fucoses, and is carried by 
glycoconjugates (glycoproteins and glycolipids) on the plasma membrane. Its chemical structure is 
Fucα1 → 2Galβ1 → 4 [Fucα1 → 3]GlcNAcβ1 → R, which belongs to the A, B, H, Lewis blood group 
antigen family with specific fucosylation of the terminal end of carbohydrate structure catalyzed by the  
α1,2-fucosyltransferase (α1,2-FUT) [1,2]. Lewis (y) antigen is expressed predominately during 
embryogenesis. Under normal physiological conditions, its expression in adults is restricted to the 
surface of granulocytes and epithelium [3]. However, overexpression of Lewis (y) antigen is 
frequently found in human cancers and has been shown to be associated with poor prognosis [4,5]. Our 
previous studies using a stably α1,2-FUT stable transfected ovarian cancer cell line RMG-1-hFUT 
have shown that Lewis (y) antigen plays a positive role in the process of invasion and metastasis of 
ovarian cancer cells [6]. Nonetheless, the mechanisms by which Lewis (y) antigen enhances the 
invasion and tumor metastasis are still unknown. 
Metastasis is a complex biological process consisting of a long series of sequential and interrelated 
steps, including the organized breakdown of the extracellular matrix (ECM) by matrix 
metalloproteinases (MMPs) [7,8]. MMPs belong to a rapidly growing family of structurally related 
endopeptidases capable of processing or degrading all ECM components. In particular, each ECM 
element is cleaved by a specific MMP or MMP group [9]. Among the human MMPs reported to date, 
MMP-2 and MMP-9 play vital roles in the degradation of the ECM because of their substrate 
specificity toward type IV collagen, the major component of basement membrane. High level 
expression of MMP-2 and MMP-9 has been frequently correlated with increased tumor invasion and 
poor prognosis in various types of human cancer [10,11]. The activity of MMPs is inhibited by specific 
tissue inhibitors of MMPs known as TIMPs. So far, four different TIMPs (TIMP-1, -2, -3 and -4) have 
been identified in humans [9]. Of these TIMPs, TIMP-1 and TIMP-2 are the best characterized TIMPs 
inhibitors of all MMPs [12]. In particular, TIMP-1 is more specific for MMP-9, and TIMP-2 regulates 
the activity of MMP-2 and MMP-9 in a concentration dependent fashion [13,14]. It is widely accepted 
that the degradation of ECM and, consequently, increased invasion capacity and metastatic potential of 
tumor cells results from the imbalance between the activities of these proteases and their   
inhibitors [15]. 
In this study, we established a stable cell line constitutively expressing Lewis (y) antigen   
(RMG-1-hFUT) by transfecting the cDNA encoding part of the human α1,2-fucosyltransferase  Int. J. Mol. Sci. 2010, 11                 
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(α1,2-FUT) gene into the ovarian cancer cell line RMG-1, and investigated whether Lewis (y) antigen 
regulates the expression of MMP-2, MMP-9, TIMP-1 and TIMP-2. 
2. Results 
2.1. Overexpression of Lewis (y) Antigen Enhances Migration of RMG-1 Ovarian Cancer Cells 
In our pervious study, RMG-1-hFUT cells established by transfection with the hFUT gene were 
shown to express Lewis (y) antigen at a significantly higher level than the original RMG-1 cells [16]. 
Thus, we next determined the impact of Lewis (y) antigen overexpression on the invasive ability of 
RMG-1 cells. In vitro transwell assay indicated that RMG-1-hFUT cells exhibited higher invasive 
ability than control cells (Figure 1). These data suggested that Lewis (y) antigen enhanced the 
metastatic potential of RMG-1 ovarian cancer cells. 
Figure 1. In vitro migration assay was performed by using 24-well transwell units coated 
with Matrigel. Invaded cell number was determined after cell seeding. * P < 0.05. 
 
2.2. Down-Regulation of TIMPs and up-Regulation of MMPs by Lewis (y) Antigen 
To explore the possible mechanisms of Lewis (y) antigen enhanced migration, we further tested the 
mRNA and protein levels of TIMP-1, TIMP-2, MMP-2 and MMP-9 in RMG-1-hFUT and RMG-1 
cells by using quantitative Real-Time RT-PCR and Western blot analysis, respectively. As shown in 
Figure 2a, the mRNA level of these two TIMPs was significantly reduced, whereas the mRNA level of 
the two MMPs was markedly increased. Meanwhile, changes observed by Western blotting were in 
accordance with the findings in the quantitative real-time RT-PCR study (Figure 2b). 
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Figure 2. Expression of MMP-2, MMP-9, TIMP-1 and TIMP-2 in RMG-1 and   
RMG-1-hFUT cells shown by quantitative Real-Time RT-PCR (a) and Western blot 
analysis (b). (a) According to quantitative Real-Time RT-PCR, the mRNA level of these 
two TIMPs was significantly reduced, but the mRNA level of the two MMPs was 
markedly increased in RMG-1-hFUT cells, compared with RMG-1 cells (b) Protein levels 
of  
MMP-2, MMP-9, TIMP-1 and TIMP-2, determined by Western blot, were consistent with 
the mRNA levels. Representative blots are shown, and protein size is expressed in kDa.  
* P < 0.05, ** P < 0.01. 
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Furthermore, measurement of TIMP-1 and TIMP-2 concentrations in the culture supernatants by 
ELISA and statistical analysis of the data showed a diminution of TIMP-1 and TIMP-2 secretion in 
RMG-1-hFUT when compared with RMG-1 cells (Figure 3, P < 0.01). 
Figure 3. TIMP-1 and TIMP-2 concentrations as measured in the culture supernatants by 
ELISA. A diminution of TIMP-1 and TIMP-2 secretion was observed in RMG-1-hFUT 
when compared with RMG-1 cells. ** P < 0.01. 
 
To further demonstrate the association between Lewis (y) antigen and the expression of TIMP-1, 
TIMP-2, MMP-2 and MMP-9, anti-Lewis (y) antigen monoclonal antibody was used to block the 
Lewis (y) antigen present on the surface of RMG-1-hFUT cells. As shown in Figure 4, after   
RMG-1-hFUT cells were treated with anti-Lewis (y) antigen monoclonal antibody, the expression Int. J. Mol. Sci. 2010, 11                 
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levels of TIMP-1 and TIMP-2 were increased, but the expression levels of MMP-2 and MMP-9   
were decreased.  
All these findings suggested that overexpression of Lewis (y) antigen inhibited the expression 
TIMP-1 and TIMP-2, but increased the expression of MMP-2 and MMP-9. 
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Figure 4. Protein levels of MMP-2, MMP-9, TIMP-1 and TIMP-2 in RMG-1 and   
RMG-1-hFUT cells treated with anti-Lewis (y) antibody. (a) A representative Western blot 
of three independent and reproducible experiments. Lane 1. RMG-1 cells; 2. RMG-1 cells 
+ antibody; 3. RMG-1-hFUT cells; 4. RMG-1-hFUT cells + antibody. (b) Quantitative data 
were expressed as the intensity ratio target genes to GAPDH. * vs. RMG-1 cells,   
* P < 0.05, ** P < 0.01; 
▲ vs. RGM-1-hFUT cells, 
▲P < 0.05, 
▲▲ P < 0.01. 
 
 
3. Discussion 
As described in our previous papers, we successfully transfected the α1,2-FUT gene into human 
ovarian carcinoma-derived RMG-1 cells, which contain a significantly high amount of Lewis (x), the 
precursor of Lewis (y), and established RMG-1-hFUT cells with higher expression level of Le (y) Int. J. Mol. Sci. 2010, 11                 
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compared with RMG-1 cells. Our further experiments demonstrated that RMG-1-hFUT cells not only 
exhibited increased proliferation and invasion capacity, but also showed high tolerance to common 
chemotherapy drugs for ovarian cancer, such as carboplatin, 5-fluorouracil and taxol [16–19]. 
However, the molecular mechanisms by which Lewis (y) causes these malignant properties of human 
ovarian cancer cells have not been completely understood. The present study is the first to address the 
mechanism by which Lewis (y) promotes tumor invasion and metastasis. We found that changes in 
expression of TIMP-1, TIMP-2, MMP-2 and MMP-9 are involved in the enhancement of cell invasion 
by Lewis (y). 
Despite overexpression and invasion promoting ability of Lewis (y), and MMP-2 and MMP-9 being 
separately reported in various types of human cancer, a direct association between Lewis (y) and these 
two TIMPs has never been described. In this study, we showed that overexpression of Lewis (y) 
increased MMP-2 and MMP-9 expression to promote migration and invasion of ovarian cancer cells. 
Furthermore, we also found that the expression of TIMP-1 and TIMP-2 was inhibited by 
overexpression of Lewis (y). These results suggest that MMPs/TIMPs play a crucial role in Lewis (y) 
antigen-mediated cell invasion. Our previous microarray study indicated that a number of genes 
associated with metastasis are differentially expressed in RMG-1-hFUT cells, compared with those in 
RMG-1 cells [6]. In addition to MMPs and TIMPs, Lewis (y) antigen may also promote cell invasion 
via other mechanisms. Moreover, we also noted a significant increase of TIMP-1 and TIMP-2 in  
RMG-1 cell treated with anti-Lewis monoclonal antibody, which is probably because of the 
endogenous expression of Lewis (y) in RMG-1 cells [18]. 
More recently, Javier et al. have demonstrated that MMP-9, more specifically the hemopexin 
domain, has anti-apoptotic effects on cancer cells [20]. Thus, the elevation of MMP-9 not only 
contributes to the enhancement of cell invasion, but also maintains the malignant properties of   
RMG-1-hFUT cells. In addition, there is growing evidence that the epidermal growth factor receptor 
pathway and PI3K/Akt signal transduction pathway are key regulators of TIMP/MMP balance [21,22]. 
We have previously showed that Lewis(y) antigen stimulates the growth of ovarian cancer cells via 
regulation of the epidermal growth factor receptor pathway and the PI3K/Akt signaling pathway 
[18,19]. It therefore seems reasonable to propose that activation of the PI3K/Akt signaling pathway 
may represent one underlying mechanism for the Lewis (y) antigen-mediated cell invasion by 
regulating the expression of TIMPs and MMPs. However, the mechanisms by which Lewis (y) 
regulates the TIMPs and MMPs need further to be elucidated.  
4. Experimental Section 
4.1. Cell Culture 
The human ovarian cancer cell line, RMG-1, was kindly provided by Professor Iwamori Masao 
(Tokyo University, Japan). RMG-1-hFUT cell line, highly expressing Lewis (y) antigen, was 
established by transfecting the pcDNA3.1 (-)-HFUT-H expression vector (containing a1,2-FUT gene) 
into RMG-1 cells as previously described [16,17]. Cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM, Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum 
(FBS, Hyclone, Logan, UT, USA) at 37 °C in a humidified 5% CO2 atmosphere. Cells were routinely 
passaged, and cells at logarithmic growth phase were used for further experiments. Int. J. Mol. Sci. 2010, 11                 
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4.2. RNA Isolation and Quantitative Real-Time RT-PCR 
Total RNA from treated cells was isolated using Trizol reagent (Life Technologies, Inc., Rockville, 
MD). RNA (2 µg) was converted to complementary DNA (cDNA) using the RT-PCR kit (TAKARA 
Bio., Dalian, China), according to the manufacturer’s protocol. Then the cDNA was subjected to   
Real-Time PCR analysis using the SYBR Green PCR Master Mix (TAKARA Bio., Dalian, China) on 
the ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The 
PCR primer sequences were designed according to the human MMP-2, MMP-9, TIMP-1 and TIMP-2 
gene sequences reported in GenBank and chemically synthesized (Table 1). The specificity of the PCR 
was confirmed by examining the dissociation reaction plot subsequent to Real-Time RT-PCR. Human 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as the constitutive control. PCR 
reactions of each sample were done in triplicate. Data were analyzed through the comparative 
threshold cycle (CT) method. 
Table 1. Primer sequences used for quantitative Real-Time RT-PCR. 
Gene symbol  Sequences  Product size (bp) 
TIMP-1 
F: 5’-GTTGTTGCTGTGGCTGATAG-3’ 
R: 5’-TGTGGGACCTGTGGAAGTA-3’ 
266 
TIMP-2 
F: 5’-CGCTCAAATACCTTCACAA-3’ 
R: 5’-CGGCAGCAAGTCCAATA-3’ 
217 
GAPDH 
F: 5’-AAGGCTGTGGGCAAGG-3’ 
R: 5’-TGGAGGAGTGGGTGTCG-3’ 
238 
MMP-2 
F: 5’-TTGACGGTAAGGACGGACTC-3’ 
R: 5’-ACTTGCAGTACTCCCCATCG-3’ 
153 
MMP-9 
F: 5’-TTGACAGCGACAAGAAGTGG-3’ 
R: 5’-GCCATTCACGTCGTCCTTAT-3’ 
179 
4.3. Western Blot Analysis 
Total proteins from cells were separated on SDS-polyacrylamide gels and then electro-transferred 
to PVDF membranes. MMP and TIMP proteins were visualized by immunodetection using 
monoclonal MMP-1, MMP-2 (Abcam, Cambridge, MA, USA, dilution 1:2,000), TIMP-1, or TIMP-2 
(Santa Cruz Biotechnology, CA, USA, dilution 1:2,000) antibodies. After subsequent incubation with 
horseradish peroxidase-linked secondary antibodies, the labeled proteins were detected using an 
enhanced chemiluminescence (ECL) kit (Amersham-Pharmacia, Freiburg, Germany). 
4.4. Cell Migration Assay 
Migration assays were conducted in 24-well plate applying Transwell cell culture chambers (8 mm 
pore size; Costar, Cambridge, MA, USA). Matrigel-coated Transwell inserts were prepared by adding 
100 μL of Matrigel (250 μg/mL) to the Transwell and allowing the Matrigel to dry at 37 °C for 12 h. 
Harvested cells at a density of 1 × 10
5 were seeded in the upper well with 100 μL medium 
supplemented with 10% FBS. The same medium was placed in the lower chamber. At the end of the 
24-hour incubation at 37 °C, 5% CO2, cells on the top of the membrane were removed by swiping with Int. J. Mol. Sci. 2010, 11                 
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a damp cotton swab, and cells that had migrated to the lower surface were fixed in methanol for  
15 minutes at room temperature and stained with H&E. Cell migration was quantified by counting the 
migrated cells on the lower surface of the membrane in ten individual fields using a 400× objective. 
4.5. Anti-Lewis (y) Antigen Antibody Blocking Test 
Cultured RMG-1 or RMG-1-hFUT cells in exponential growth phase were harvested to prepare 
single cell suspension, and mouse anti-human Lewis (y) monoclonal antibodies (Abcam, UK) was then 
added at a final concentration of 10 μg/mL. After incubation at 37 °C for 30 min, cells were harvested. 
Proteins were isolated and Western blot analysis was performed to detect the expression of MMP-2, 
MMP-9, TIMP-1 and TIMP-2 proteins. 
4.6. ELISA 
TIMP-1 and TIMP-2 levels in the culture supernatants were assayed using commercially available 
human TIMP ELISA test kits (NeoBioscience, Shenzhen, China) according to the manufacturer’s 
recommendations. The results were finally expressed as the mean ng/mL ± standard errors. 
4.7. Statistical Analysis 
All experiments were performed in triplicate and all data are expressed as mean ± standard errors. 
Raw data were analyzed by the unpaired Student’s t test using SPSS 11.0 software (SPSS Inc., 
Chicago, IL, USA). A P-value < 0.05 was considered to be statistically significant. 
5. Conclusions 
In summary, we showed that overexpression of Lewis (y) promotes the invasion and metastasis of 
ovarian cancer cells, and down-regulation of TIMPs and up-regulation of MMPs may be involved in 
these processes. Although the specific mechanisms still need to be further studied, our results raise the 
possibility that inhibition of Lewis (y) antigen may suppress tumor invasion and metastasis. 
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